SAN FRANCISCO, CA—A blockchain-based drug product tracking network can meet the Drug Supply Chain Security Act (DSCSA) by 2023, according to report released by the MediLedger Pilot Project. The FDA’s DSCSA pilot project program selected various participants to explore and evaluate methods to enhance the safety and security of the drug supply chain. The MediLedger Pilot Project was comprised of 25 companies that evaluated blockchain technologies like the MediLedger Network to track and trace prescription drugs across the US pharmaceutical supply chain. The final report proposed business rules and standards on how share data and using a blockchain-based network to enforce those standards. To read the full report, please visit www.mediledger.com/fda-pilot-project.